Elbit Imaging Ltd (EMITF)

[midastouch017]

Elbit Imaging Ltd. Announces FDA Approval Extension of Insightec's Exablate Neuro for Treatment of Essential Tremor


TEL AVIV, ISREAL / ACCESSWIRE / April 24, 2017 / Elbit Imaging Ltd. (EMITF.TA) (EMITF) ("Elbit" or the "Company") announced today, in furtherance to the announcements dated on October 22, 2015 and July 12, 2016, that it was informed by INSIGHTEC Ltd. ("INSIGHTEC"), that the FDA has extended its approval of Exablate Neuro system for a non-invasive treatment of essential tremor in patients who have not responded to medication and now it's including the usage on 1.5 Tesla MRI systems (the FDA approval which was announced on July 12, 2016, was given for the usage of the Exablate Neuro on 3 Tesla magnet strength MRI systems). The above-mentioned extension is expected to expend the product's markets of which Exablate Neuro is applicable for.

Exablate Neuro uses focused ultrasound waves to precisely target and ablate tissue deep within the brain with no incisions or implants. The treatment is done under MRI guidance for real time treatment monitoring.

Essential tremor is the most common movement disorder, affecting more than 5 million people in the United States, and millions more worldwide. Hand tremor is the most common symptom, but tremors can also affect the head, arms, voice, legs, and torso. For these patients, performing everyday tasks presents a challenge and impacts their quality of life.

The Company holds approximately 89.9% of the share capital of Elbit Medical Technologies Ltd. (TASE:EMTC-M) (85.8% on a fully diluted basis) which, in turn, holds approximately 31.3% of the share capital in INSIGHTEC (26.6% on a fully diluted basis).